scholarly journals Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: A randomized prospective trial

Cancer ◽  
2008 ◽  
Vol 112 (2) ◽  
pp. 443-444 ◽  
Author(s):  
David Kissane ◽  
Yuelin Li
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Group Therapy ◽  
Prospective Trial ◽  
Metastatic Breast ◽  
Randomized Prospective Trial

scholarly journals Reply to Effects of Supportive-Expressive Group Therapy on Survival of Patients with Metastatic Breast Cancer: A Randomized Prospective Trial

Cancer ◽  
2008 ◽  
Vol 112 (2) ◽  
pp. 444-444
Author(s):  
David Spiegel ◽  
Lisa D. Butler ◽  
Janine Giese-Davis ◽  
Cheryl Koopman ◽  
Elaine Miller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Group Therapy ◽  
Prospective Trial ◽  
Metastatic Breast ◽  
Randomized Prospective Trial

scholarly journals Responsiveness to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer

2007 ◽  
Vol 16 (8) ◽  
pp. 1451-1451
Author(s):  
Julie Lemieux ◽  
Dorcas E. Beaton ◽  
Sheilah Hogg-Johnson ◽  
Louise J. Bordeleau ◽  
Jon Hunter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Group Therapy ◽  
Disease Progression ◽  
Metastatic Breast ◽  
Responsiveness To Change

Circulating tumour markers and time to progression in the chemotherapy treatment of metastatic breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10674-10674
Author(s):  
M. Ruiz-Lopez-tejada ◽  
L. Tejedor-Cabrera ◽  
C. Iradi-Martinez
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Disease Control ◽  
Prospective Trial ◽  
Metastatic Breast ◽  
Tumour Markers ◽  
Chemotherapy Treatment ◽  
Biological Behaviour ◽  
Kaplan Meier ◽  
Biological Patterns

10674 Background: Monitoring the response to the chemotherapy treatment (CT) in metastatic breast cancer (MBC) by circulating tumour markers (CTM) remains under investigation. We have previosly shown that early lack of biological progression of 4 CTM (1 oncofetal: CEA, 2 mucin related: CA 15.3,CA 549 and cytokeratin 18–19: TPA), predicts anatomic disease control - concordance nearly 100% for every CTM- during CT of MBC (E.J.C. Suppl Oct 2005, Vol 3 Abst 415- ECCO 13). The aim is to evaluate whether the biological behaviour predicts time till progression (TTP), as reliable parameter of the quality of response (QR). Methods: In 106 consecutive courses of different schedules of CT given along 3 years in our Hospital to 55 patients with progressive MBC, we conducted a prospective trial analysing these 4 CTM every 3 weeks before CT infusions and performing CTM concentration / time curves. TTP was calculated by Kaplan Meier method -SPSS 11-. Bio kinetic change has been defined as a lineal slope that includes 2 early and consecutive changes of at least 25% of CTM start value. The analysis covered 604 cycles, 405 curves and 2417 marker determinations. Results: Ninety six per cent of the cases have progressed after their CT courses. In CTM expressing diseases, and sometimes after a no more than 3 weeks paradoxical period, three biological patterns could be detected according to directional possibilities: progressive elevation (Bio P), progressive download (Bio R) and stabilization -without bio kinetic change- (Bio S). Table shows the TTP median values in the different group of cases with the same CTM Bio response patterns; Biological Patterns and TTP Kaplan Meier curves will be shown as a Poster at the meeting. Conclusions: In CTM expressing tumours and taking into account simple kinetics criteria, the dynamic analysis of CTM before infusions can early estimates TTP, adding complemmentary information to the disease control prediction in the evaluation of the QR during the CT of MBC. [Table: see text] No significant financial relationships to disclose.

Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 659-659
Author(s):  
S. R. Amin ◽  
V. Valero ◽  
E. Rivera ◽  
R. Adinin ◽  
R. Banay ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Prospective Trial ◽  
Metastatic Breast ◽  
Weekly Docetaxel ◽  
Ophthalmologic Examination ◽  
Silicone Intubation ◽  
Canalicular Stenosis ◽  
Weekly Group ◽  
Lacrimal Drainage

659 Background: To determine the incidence and severity of epiphora and canalicular stenosis in patients receiving weekly or every-3-weekly docetaxel. Methods: In this prospective trial, each patient underwent an ophthalmologic examination and probing and irrigation of the lacrimal drainage apparatus at baseline and at every 4–6 weeks after initiation of docetaxel. During each visit, epiphora and canalicular stenosis were graded. Patients with epiphora were treated with Tobradex drops. If epiphora worsened or findings on probing and irrigation suggested further canalicular narrowing, silicone intubation was offered. Results: 28 patients received weekly and 28 patients received every-3-weeks docetaxel. 18(64%) patients who received weekly docetaxel developed epiphora. Epiphora was mild in 7 patients, moderate in 5, and severe in 6. Nine patients had resolution of epiphora with Tobradex. Nine patients had worsened canalicular stenosis; 6 underwent surgery. The median cumulative docetaxel dose was 496.5 mg at onset of epiphora and 889.5 mg at surgery. 11 (39%) patients who received every-3-weeks docetaxel developed epiphora. The median cumulative docetaxel dose at the time of onset of epiphora in this group was 420 mg. Epiphora was mild in 9 patients, moderate in 1, and severe in 1. Nine patients had resolution of epiphora in response to Tobradex. Two patients underwent surgery. Conclusions: Epiphora occurred in 64% of patients in the weekly group and 39% of patients in the every-three-weeks group. Moderate or severe canalicular stenosis was seen in about one-third of patients in the weekly group and none of the patients in the every-3-weeks group. [Table: see text]

scholarly journals Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer

Cancer ◽  
2007 ◽  
Vol 110 (5) ◽  
pp. 1130-1138 ◽  
Author(s):  
David Spiegel ◽  
Lisa D. Butler ◽  
Janine Giese-Davis ◽  
Cheryl Koopman ◽  
Elaine Miller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Group Therapy ◽  
Metastatic Breast

Therapy With Women With Metastatic Breast Cancer

2005 ◽  
Vol 13 (1) ◽  
pp. 50-53
Author(s):  
Bronwen Beacham ◽  
Christine Hill ◽  
Fiona Mcdermott ◽  
Mary O'Brien ◽  
Jane Turner
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Metastatic Breast Cancer ◽  
Group Therapy ◽  
Physical State ◽  
Death And Dying ◽  
Metastatic Breast ◽  
Sense Of Control ◽  
State Of Health

Objective: To describe some clinical issues encountered in individual and group therapy with women with metastatic breast cancer. Conclusions: The pressure to ‘keep positive’ poses dilemmas for patients and therapists alike, whether in individual or group therapy. The basis of skilled supportive care rests on the ability of therapists to assist patients and their families to face death rather than avoid it. Paradoxically, facing issues of death and dying leads to a greater sense of control, and empowers patients to reorder life's priorities, thus improving quality of life and relationships. In addition to the obvious need to detect and treat illness such as depression, working with women with metastatic breast cancer requires flexibility on the part of the therapist to adapt to her physical state of health, to include partners and family members where possible, and to liaise with colleagues in the treating team to facilitate communication and understanding of specific difficulties that may be encountered.

Sign in / Sign up

Export Citation Format

Share Document